Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Icosavax, Inc. ICVX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
55/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$27.00
+76.4%

Icosavax, Inc. (ICVX) is a Biotechnology company in the Healthcare sector, currently trading at $15.31. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ICVX = $27 (+76.4% upside).

Financials: revenue is $582,000, +145.1%/yr average growth. Net income is $88M (loss), growing at -184.6%/yr. Net profit margin is -15199% (negative). Gross margin is -216.7% (+776.6 pp trend).

Balance sheet: total debt is $9M against $218M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 16.24 (strong liquidity). Debt-to-assets is 3.7%. Total assets: $239M.

Analyst outlook: 5 / 6 analysts rate ICVX as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 21/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).

$27.00
▲ 76.36% Upside
Average Price Target
The 12-month price target for Icosavax, Inc. is $27.00.

ICVX SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ICVX

✓
VALUE Pass
100/100
ICVX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $27, implying +76.4% from the current price $15. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
ICVX: +145.1%/yr revenue is, -184.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ICVX: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 16.24 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
ICVX: Gross margin is -216.7% (+776.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 5 / 6 analysts rate ICVX as buy (83%). Analyst consensus target is $27 (+76.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ICVX: Net profit margin is -15199%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.75-16.105
Volume8.56M
Avg Volume (30D)1.05M
Market Cap$769.04M
Beta (1Y)1.28
Share Statistics
EPS (TTM)-2.23
Shares Outstanding$39.73M
IPO Date2021-07-29
Employees60
CEOAdam K. Simpson
Financial Highlights & Ratios
Revenue (TTM)$582K
Gross Profit$-1.26M
EBITDA$-95.06M
Net Income$-88.46M
Operating Income$-95.06M
Total Cash$218.31M
Total Debt$8.8M
Net Debt$-50.05M
Total Assets$238.68M
Price / Earnings (P/E)-6.9
Price / Sales (P/S)1321.37
Analyst Forecast
1Y Price Target$27.00
Target High$27.00
Target Low$27.00
Upside+76.4%
Rating ConsensusBuy
Analysts Covering6
Buy 83% Hold 17% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS45114M1099

Price Chart

Track all markets on TradingView
ICVX
Icosavax, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
4.75 52WK RANGE 16.11

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 IMMX
IMMX
Immix Biopharma, Inc.
$9.85
+1.65%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.20
-0.62%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.68
+6.77%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message